Health Utility Scores of Atopic Dermatitis in US Adults

Jonathan I. Silverberg, Joel M. Gelfand, David J. Margolis, Mark Boguniewicz, Luz Fonacier, Mitchell H. Grayson, Peck Y. Ong, Zelma Chiesa Fuxench, Eric Simpson

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: The impact of atopic dermatitis (AD) on health-related quality of life and health utility in the US adult population is not well established. Objective: To determine the health utilities and quality-adjusted life-years (QALYs) lost in adults with AD versus without AD in the US population. Methods: A cross-sectional, population-based study of 3495 adults was performed. AD was determined using modified UK diagnostic criteria for AD. AD severity was assessed using self-reported global AD severity, the Patient-Oriented Eczema Measure, the Patient-Oriented Scoring AD, and the Patient-Oriented Scoring AD itch and sleep. Six-dimensional health state short form (SF-6D) health utility scores and total QALY loss were assessed. Results: The mean SF-6D score was lower in adults with AD compared with healthy adults (0.69 [95% CI, 0.68-0.70] versus 0.79 [95% CI, 0.77-0.79]). In particular, those with moderate-to-severe AD (mean, 0.53-0.66) had similar or lower SF-6D scores compared with those with all other self-reported disorders examined, except autoimmune disorders. Adults with AD and atopic comorbidities had significantly lower SF-6D scores compared with those without atopic comorbidities. Among the 7 disorders examined, AD was associated with higher total QALY loss than autoimmune disorders, diabetes, food allergy, and heart disease in both males and females. The largest QALY loss was for moderate AD in females and mild AD in males. Conclusions: Moderate-to-severe AD is associated with significant decrements of health utility in the US population. These data illustrate the heavy societal burden of moderate and severe AD and provide important insight for prioritization of resource allocation and cost-effectiveness research.

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology: In Practice
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Atopic Dermatitis
Health
Quality-Adjusted Life Years
Population
Comorbidity
Food Hypersensitivity
Resource Allocation
Eczema
Type 1 Diabetes Mellitus
Cost-Benefit Analysis

Keywords

  • Atopic dermatitis
  • Eczema
  • Epidemiology
  • Health-related quality of life
  • Patient burden
  • Quality-adjusted life-years
  • Utility

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Silverberg, J. I., Gelfand, J. M., Margolis, D. J., Boguniewicz, M., Fonacier, L., Grayson, M. H., ... Simpson, E. (Accepted/In press). Health Utility Scores of Atopic Dermatitis in US Adults. Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2018.11.043

Health Utility Scores of Atopic Dermatitis in US Adults. / Silverberg, Jonathan I.; Gelfand, Joel M.; Margolis, David J.; Boguniewicz, Mark; Fonacier, Luz; Grayson, Mitchell H.; Ong, Peck Y.; Fuxench, Zelma Chiesa; Simpson, Eric.

In: Journal of Allergy and Clinical Immunology: In Practice, 01.01.2019.

Research output: Contribution to journalArticle

Silverberg, JI, Gelfand, JM, Margolis, DJ, Boguniewicz, M, Fonacier, L, Grayson, MH, Ong, PY, Fuxench, ZC & Simpson, E 2019, 'Health Utility Scores of Atopic Dermatitis in US Adults', Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2018.11.043
Silverberg, Jonathan I. ; Gelfand, Joel M. ; Margolis, David J. ; Boguniewicz, Mark ; Fonacier, Luz ; Grayson, Mitchell H. ; Ong, Peck Y. ; Fuxench, Zelma Chiesa ; Simpson, Eric. / Health Utility Scores of Atopic Dermatitis in US Adults. In: Journal of Allergy and Clinical Immunology: In Practice. 2019.
@article{6b05aba956d94101ae6c32aaa54aae5c,
title = "Health Utility Scores of Atopic Dermatitis in US Adults",
abstract = "Background: The impact of atopic dermatitis (AD) on health-related quality of life and health utility in the US adult population is not well established. Objective: To determine the health utilities and quality-adjusted life-years (QALYs) lost in adults with AD versus without AD in the US population. Methods: A cross-sectional, population-based study of 3495 adults was performed. AD was determined using modified UK diagnostic criteria for AD. AD severity was assessed using self-reported global AD severity, the Patient-Oriented Eczema Measure, the Patient-Oriented Scoring AD, and the Patient-Oriented Scoring AD itch and sleep. Six-dimensional health state short form (SF-6D) health utility scores and total QALY loss were assessed. Results: The mean SF-6D score was lower in adults with AD compared with healthy adults (0.69 [95{\%} CI, 0.68-0.70] versus 0.79 [95{\%} CI, 0.77-0.79]). In particular, those with moderate-to-severe AD (mean, 0.53-0.66) had similar or lower SF-6D scores compared with those with all other self-reported disorders examined, except autoimmune disorders. Adults with AD and atopic comorbidities had significantly lower SF-6D scores compared with those without atopic comorbidities. Among the 7 disorders examined, AD was associated with higher total QALY loss than autoimmune disorders, diabetes, food allergy, and heart disease in both males and females. The largest QALY loss was for moderate AD in females and mild AD in males. Conclusions: Moderate-to-severe AD is associated with significant decrements of health utility in the US population. These data illustrate the heavy societal burden of moderate and severe AD and provide important insight for prioritization of resource allocation and cost-effectiveness research.",
keywords = "Atopic dermatitis, Eczema, Epidemiology, Health-related quality of life, Patient burden, Quality-adjusted life-years, Utility",
author = "Silverberg, {Jonathan I.} and Gelfand, {Joel M.} and Margolis, {David J.} and Mark Boguniewicz and Luz Fonacier and Grayson, {Mitchell H.} and Ong, {Peck Y.} and Fuxench, {Zelma Chiesa} and Eric Simpson",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jaip.2018.11.043",
language = "English (US)",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",

}

TY - JOUR

T1 - Health Utility Scores of Atopic Dermatitis in US Adults

AU - Silverberg, Jonathan I.

AU - Gelfand, Joel M.

AU - Margolis, David J.

AU - Boguniewicz, Mark

AU - Fonacier, Luz

AU - Grayson, Mitchell H.

AU - Ong, Peck Y.

AU - Fuxench, Zelma Chiesa

AU - Simpson, Eric

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The impact of atopic dermatitis (AD) on health-related quality of life and health utility in the US adult population is not well established. Objective: To determine the health utilities and quality-adjusted life-years (QALYs) lost in adults with AD versus without AD in the US population. Methods: A cross-sectional, population-based study of 3495 adults was performed. AD was determined using modified UK diagnostic criteria for AD. AD severity was assessed using self-reported global AD severity, the Patient-Oriented Eczema Measure, the Patient-Oriented Scoring AD, and the Patient-Oriented Scoring AD itch and sleep. Six-dimensional health state short form (SF-6D) health utility scores and total QALY loss were assessed. Results: The mean SF-6D score was lower in adults with AD compared with healthy adults (0.69 [95% CI, 0.68-0.70] versus 0.79 [95% CI, 0.77-0.79]). In particular, those with moderate-to-severe AD (mean, 0.53-0.66) had similar or lower SF-6D scores compared with those with all other self-reported disorders examined, except autoimmune disorders. Adults with AD and atopic comorbidities had significantly lower SF-6D scores compared with those without atopic comorbidities. Among the 7 disorders examined, AD was associated with higher total QALY loss than autoimmune disorders, diabetes, food allergy, and heart disease in both males and females. The largest QALY loss was for moderate AD in females and mild AD in males. Conclusions: Moderate-to-severe AD is associated with significant decrements of health utility in the US population. These data illustrate the heavy societal burden of moderate and severe AD and provide important insight for prioritization of resource allocation and cost-effectiveness research.

AB - Background: The impact of atopic dermatitis (AD) on health-related quality of life and health utility in the US adult population is not well established. Objective: To determine the health utilities and quality-adjusted life-years (QALYs) lost in adults with AD versus without AD in the US population. Methods: A cross-sectional, population-based study of 3495 adults was performed. AD was determined using modified UK diagnostic criteria for AD. AD severity was assessed using self-reported global AD severity, the Patient-Oriented Eczema Measure, the Patient-Oriented Scoring AD, and the Patient-Oriented Scoring AD itch and sleep. Six-dimensional health state short form (SF-6D) health utility scores and total QALY loss were assessed. Results: The mean SF-6D score was lower in adults with AD compared with healthy adults (0.69 [95% CI, 0.68-0.70] versus 0.79 [95% CI, 0.77-0.79]). In particular, those with moderate-to-severe AD (mean, 0.53-0.66) had similar or lower SF-6D scores compared with those with all other self-reported disorders examined, except autoimmune disorders. Adults with AD and atopic comorbidities had significantly lower SF-6D scores compared with those without atopic comorbidities. Among the 7 disorders examined, AD was associated with higher total QALY loss than autoimmune disorders, diabetes, food allergy, and heart disease in both males and females. The largest QALY loss was for moderate AD in females and mild AD in males. Conclusions: Moderate-to-severe AD is associated with significant decrements of health utility in the US population. These data illustrate the heavy societal burden of moderate and severe AD and provide important insight for prioritization of resource allocation and cost-effectiveness research.

KW - Atopic dermatitis

KW - Eczema

KW - Epidemiology

KW - Health-related quality of life

KW - Patient burden

KW - Quality-adjusted life-years

KW - Utility

UR - http://www.scopus.com/inward/record.url?scp=85060326604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060326604&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2018.11.043

DO - 10.1016/j.jaip.2018.11.043

M3 - Article

C2 - 30537560

AN - SCOPUS:85060326604

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

ER -